Cellectar Biosciences (CLRB) Operating Expenses (2010 - 2026)
Cellectar Biosciences (CLRB) posted Operating Expenses of $5.7 million for Q4 2025, up 17.32% sequentially from $4.9 million in Q3 2025, and down 55.35% YoY from $12.7 million in Q4 2024.
Cellectar Biosciences (CLRB) Operating Expenses (2010 - 2026) Analysis & Trends
Cellectar Biosciences has reported Operating Expenses for 16 years, with the latest figure at $5.7 million in Q4 2025.
- Quarterly Operating Expenses fell 55.35% year-over-year to $5.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $23.0 million (down 55.62% YoY) and the FY2025 annual result came in at $23.0 million, down 55.62% from the prior year.
- Operating Expenses improved to $5.7 million in Q4 2025 per CLRB's latest filing, from $4.9 million in the prior quarter.
- Over five years, Operating Expenses peaked at $13.7 million in Q2 2024 and troughed at $4.9 million in Q3 2025.
- A 5-year average of $8.3 million and a median of $7.4 million in 2022 frame the typical range for Operating Expenses.
- The sharpest annual moves came in 2023 and 2025: Operating Expenses jumped 69.05% in 2023, then tumbled 63.6% in 2025.
- Over 5 years, Operating Expenses stood at $5.9 million in 2021, then gained by 25.31% to $7.4 million in 2022, then surged by 69.05% to $12.5 million in 2023, then increased by 1.57% to $12.7 million in 2024, then slumped by 55.35% to $5.7 million in 2025.
- According to Business Quant data, Operating Expenses over the past three periods registered $5.7 million, $4.9 million, and $6.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.39 Bn | 132.54 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 86.47 Bn | 78.47 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 65.25 Bn | 60.07 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 61.79 Bn | 56.66 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 42.27 Bn | 37.17 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 31.17 Bn | 27.86 Bn | 992.69 Mn | 1.06 Bn |
| 7 | BioNTech SE | 28.61 Bn | 10.22 Bn | 668.28 Mn | -784.57 Mn |
| 8 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | 427.03 Mn |
| 9 | Royalty Pharma | 27.30 Bn | 26.46 Bn | - | 541.02 Mn |
| 10 | Cellectar Biosciences | 6.77 Mn | 6.77 Mn | - | 7.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.20 Mn |
| Dec 31, 2025 | 5.69 Mn |
| Sep 30, 2025 | 4.85 Mn |
| Jun 30, 2025 | 6.04 Mn |
| Mar 31, 2025 | 6.40 Mn |
| Dec 31, 2024 | 12.74 Mn |
| Sep 30, 2024 | 13.33 Mn |
| Jun 30, 2024 | 13.70 Mn |
| Mar 31, 2024 | 12.00 Mn |
| Dec 31, 2023 | 12.55 Mn |
| Sep 30, 2023 | 9.41 Mn |
| Jun 30, 2023 | 8.29 Mn |
| Mar 31, 2023 | 8.71 Mn |
| Dec 31, 2022 | 7.42 Mn |
| Sep 30, 2022 | 7.82 Mn |
| Jun 30, 2022 | 7.44 Mn |
| Mar 31, 2022 | 6.14 Mn |
| Dec 31, 2021 | 5.92 Mn |
| Sep 30, 2021 | 5.82 Mn |
| Jun 30, 2021 | 6.03 Mn |